CAR-T treatment for advanced stomach or pancreatic cancer
Part of Cancer clinical trials.
This trial tests a customized immune-cell treatment (CAR-T) for advanced stomach or pancreatic cancer that cannot be removed by surgery. It aims to use cells engineered to target a specific tumor marker to shrink cancer or slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old
- Your cancer is confirmed as gastric (stomach) or pancreatic cancer that cannot be removed by surgery (locally advanced, recurrent, or metastatic)
- Your scans show at least one measurable tumor area, and tissue testing shows claudin 18.2 is moderately to highly present
- You have already had standard first- and second-line treatments, and surgery/curative treatment is not suitable (or you refuse surgery)
- Your overall health is fairly strong (ECOG 0–2) and you’re expected to live more than 3 months
- Blood work and organ/heart/lung tests meet safety thresholds, and you can safely donate blood for the treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests CAR-T cells that are engineered to recognize several cancer “markers” (specific proteins) found on some advanced cancers. It may help by directing the patient’s own immune cells to attack cancer, but eligibility depends on matching the required protein markers.
This trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers on cancer cells at once. The goal is to help patients with advanced solid tumors where standard treatments have stopped working or aren't an option.
This early-phase study tests a custom CAR-T cell therapy made to target EGFR in people with advanced non-small cell lung cancer. You may be eligible if your tumor has specific lab markers (EGFR and CXCL13) and if your overall heart, liver, kidney, and blood counts can safely support treatment.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
This trial tests a new type of immunotherapy called CAR-T cells, which are engineered to target a protein (Claudin18.2) found on some stomach and pancreatic cancer cells. The goal is to see if these specially designed cells can shrink tumors and slow the cancer's growth.
This trial tests a special type of immune therapy called CAR-T, which uses your own blood cells to attack cancer cells that have a specific marker, Claudin 18.2. It may be an option for people with advanced solid tumors (especially pancreatic cancer) that have not responded to other treatments.
Hear when a new Advanced Pancreatic Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.